Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Alberto Gonzalez-Medina"'
Autor:
Alberto Hernando, Maria Vila-Casadesús, Yacine Bareche, Alberto Gonzalez-Medina, Francesco Mancuso, Deborah Lo Giacco, Agatha Martin, Omar Saavedra, Irene Brana, Maria Vieito, Roberta Fasani, John Stagg, Farnoosh Abbas-Aghababazadeh, Benjamin Haibe-Kains, Roger Berche, Nadia Saoudi Gonzalez, Claudia Valverde, Eva Muñoz-Couselo, Cristina Suarez, Marc Diez, Maria Elena Elez, Jaume Capdevila, Ana Oaknin, Cristina Saura, Teresa Macarulla, Joan Carles Galceran, Enriqueta Felip, Rodrigo Dienstmann, Philippe L. Bedard, Paolo Nuciforo, Joan Seoane, Josep Tabernero, Elena Garralda, Ana Vivancos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c1751ac116ff6f5b385c5cbffc82ce9
https://doi.org/10.2139/ssrn.4336842
https://doi.org/10.2139/ssrn.4336842
Autor:
Alberto Gonzalez-Medina, Andri Papakonstantinou, Judit Matito, Fiorella Ruiz-Pace, Meritxell Bellet, Anna Suñol, Miriam Arumí, Esther Zamora, Carolina Ortiz, Lucia Sanz, Patricia Gómez Pardo, Marina Gómez-Rey, Roberta Fasani, Clara Morales, Vicente Peg, Paolo Nuciforo, Rodrigo Dienstmann, Cristina Saura, Ana Vivancos, Mafalda Oliveira
Publikováno v:
Journal of Clinical Oncology. 40:1061-1061
1061 Background: Molecular characterization of LMBC for the choice of therapy and inclusion in clinical trials is frequently performed in archival biopsies procured several years before. Emerging mut secondary to therapeutic pressure are hence freque
Autor:
Andri Papakonstantinou, Alberto Gonzalez-Medina, Judit Matito, Marta Ligero, Fiorella Ruiz-Pace, Anna Suñol, Joaquin Rivero, Roberta Fasani, Mara Cruellas, Vicente Peg, Maria Borrell, Isabel Pimentel, Santiago Escriva De Romani Munoz, Judith Balmana Gelpi, Paolo Nuciforo, Rodrigo Dienstmann, Cristina Saura, Raquel Perez-Lopez, Mafalda Oliveira, Ana Vivancos
Publikováno v:
Journal of Clinical Oncology. 40:1086-1086
1086 Background: Genomic alterations driving MBC progression may be better captured by ctDNA reflecting clonal evolution, but it is currently unknow whether ctDNA analysis can replace tumor sequencing for clinical decision purposes. Aim: to study the
Autor:
Susana Cedres Perez, Garazi Serna, Juan David Assaf Pastrana, Patricia Iranzo, Ana Callejo, Nuria Pardo, Alejandro Navarro, Alex Martinez-Marti, Carlos Cabrera Galvez, Alberto Gonzalez-Medina, Roberta Fasani, Xavier Guardia, Javier Gonzalo, Caterina Carbonell, Joan Frigola, Ramon Amat, Ana Vivancos, Paolo Nuciforo, Enriqueta Felip
Publikováno v:
Journal of Clinical Oncology. 40:e20595-e20595
e20595 Background: MPM is an aggressive cancer associated with asbestos exposure. Chemotherapy has been a mainstay of therapy and recently immunotherapy has been associated with survival improvements. Chemotherapy and immunotherapy influence the tumo